Beta-Glucan Peptide

Beta-glucan peptide refers to a class of yeast- or fungus-derived immunomodulatory complexes in which a beta-(1,3/1,6)-D-glucan polysaccharide backbone is associated with, or covalently conjugated to, peptide or protein fragments from the cell wall of organisms such as Saccharomyces cerevisiae. The glucan chain acts as the principal immunologically active moiety; the peptide component can enhance solubility, receptor targeting, and intracellular processing.

Upon administration, the beta-glucan portion is recognized as a pathogen-associated molecular pattern (PAMP) by pattern recognition receptors expressed primarily on myeloid cells.

• Dectin-1 (CLEC7A): a C-type lectin receptor on macrophages, dendritic cells, and neutrophils. Its hemITAM cytoplasmic tail recruits Syk kinase upon clustering, activating the CARD9/Bcl10/Malt1 signalsome and downstream NF-kB (p65/c-Rel and RelB), MAPK (Erk, p38, Jnk), and NFAT pathways. This drives transcription of TNF-alpha, IL-6, IL-12, and IL-23.

• Complement Receptor 3 (CR3 / CD11b/CD18): binds beta-glucan at a lectin domain separate from the iC3b site (Kd approximately 50 nM) and collaborates with Dectin-1 to prime neutrophils and macrophages for enhanced cytotoxicity via Syk-dependent ROS production.

• TLR2 / TLR6 heterodimer cooperation: amplifies cytokine output in a synergistic manner with Dectin-1 signaling.

An important downstream phenomenon is trained immunity: beta-glucan reprograms monocyte chromatin through H3K4 monomethylation and trimethylation at enhancer regions of pro-inflammatory genes, mediated by the histone methyltransferase Setd7. This epigenetic remodeling, coupled with a shift to aerobic glycolysis (Warburg-like), creates a long-lived primed state that enhances responses to unrelated secondary stimuli for weeks to months after a single exposure.

The clinical evidence base for beta-glucan (the primary active component) is substantial compared to most immune supplements, though data for peptide-conjugated forms specifically remain limited and largely preclinical.

A 2019 review published in Molecules (PMC6479769) identified more than 80 published clinical trials and 177 ClinicalTrials.gov registrations evaluating beta-glucan preparations. Human trials have examined respiratory infection prophylaxis, surgical sepsis reduction, cancer adjuvant therapy, and vaccine enhancement.

Respiratory infection: A double-blind, randomized, placebo-controlled trial using yeast (1,3)-(1,6)-beta-glucan 250 mg/day showed reduced severity of upper respiratory symptoms in healthy subjects. A separate systematic review of randomized controlled trials covering fungal beta-glucans (RSC Food and Function, 2021) analyzed 30 RCTs and found that, while most individual trials reported beneficial effects, only a minority of outcome domains reached clinical relevance thresholds, and heterogeneity in preparations complicated pooled conclusions.

Trained immunity: A 2024 Frontiers in Immunology study (PMC10896952) demonstrated that Saccharomyces cerevisiae-derived ABB i16 glucan primes human primary monocytes (n=3 to 6 donors) for enhanced cytokine responses via Dectin-1/CR3/TLR4 and Raf-1/Syk/PI3K signaling, with significant anti-tumor effects in murine melanoma and bladder carcinoma models (n=5 to 7 per group).

Vaccine co-administration: A single-center RCT in Barcelona (n=72; PMC8708701) tested ABB C1, a formulation combining beta-1,3/1,6-glucan with selenium- and zinc-enriched yeast, in volunteers receiving influenza or COVID-19 vaccines over 30 to 35 days. The supplement group showed IgG levels of 21,717 AU/mL at day 35 versus 15,596 AU/mL in placebo for the COVID-19 cohort, though the trial was small and differences in T cell counts did not reach statistical significance.

In vitro NK cell data: A 2024 BMC Cancer study (PMC10938759) found that beta-(1,3)(1,6)-D-glucan at 0.1 to 1 mcg/mL increased human NK cell proliferation by 21 to 39% and drove cytotoxicity against MCF-7 breast cancer cells to 94%, though these were in vitro results with no human clinical translation yet confirmed.

Negative finding: A randomized open-label pilot (PLOS ONE, PMC4182605; n=15 healthy males, 1,000 mg/day oral for 7 days) found beta-glucan was barely detectable in serum and produced no significant changes in cytokine production or candidacidal activity, raising questions about oral bioavailability and dose sufficiency. This finding underscores the importance of preparation type, particle size, and structural form on in vivo activity.

Typical dosage: 250-500 mg (daily).

Dosing protocols for beta-glucan and beta-glucan peptide complexes vary considerably across preparations, routes, and clinical indications, and no single universally accepted standard exists.

Oral supplementation (immune support): The most commonly cited range in peer-reviewed literature and commercial research is 250 to 500 mg per day. A 2018 double-blind RCT on yeast (1,3)-(1,6)-beta-glucan used 250 mg twice daily (500 mg/day total). The PMC7770584 review summarized the tested daily dose for immune stimulation as 100 to 500 mg, with higher doses (3 g/day) reserved for cholesterol-lowering applications via viscous cereal-derived forms.

Timing: Many protocols and commercial preparations recommend morning administration on an empty stomach with a 30-minute wait before eating, based on the rationale that the absence of food may facilitate macrophage uptake in the proximal small intestine, though peer-reviewed evidence specifically validating this timing window is limited.

Cancer adjuvant (intravenous): Perioperative IV dosing studied in surgical and oncology contexts has employed approximately 0.5 to 1 mg/kg, typically over short courses, and is outside the scope of over-the-counter supplement use.

Vaccine co-administration (ABB C1 formulation): The Barcelona RCT used 750 mg of the complex preparation daily (containing approximately 517 mg beta-1,3/1,6-glucan plus mineral yeast providing selenium and zinc), administered for 30 to 35 days.

Pediatric use: Some trials in children with recurrent respiratory infections have used mushroom-derived beta-glucan formulations at age-adjusted doses over 4-week courses, but precise pediatric dosing is not well-standardized.

This information is provided for educational purposes only and does not constitute medical advice. Dosing decisions should be made in consultation with a qualified healthcare provider, particularly given variability in product purity, structural form, and individual health status.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

Beta-glucan peptide and related beta-glucan preparations are most commonly studied or reported in combination with the following agents. Evidence quality varies and is noted where relevant.

With zinc and selenium (ABB C1 formulation): The best-controlled combination evidence comes from the 2021 Barcelona RCT (PMC8708701), where yeast beta-glucan was co-administered with 100 mcg selenium and 15 mg zinc for vaccine enhancement. Selenium and zinc are independently important for lymphocyte function and may complement beta-glucan's trained immunity effects.

With bovine colostrum peptides: A 2024 in vitro study (PMC11207084) found that adding a very low dose (0.016 mg/mL) of bovine colostrum ultrafiltrate peptides to a beta-glucan-rich mushroom and botanical blend produced synergistic increases in NK and NKT cell CD69 expression (4-fold and 6-fold respectively) and amplified IL-1beta, IL-6, and TNF-alpha over 1,000-fold versus either ingredient alone. This data is preclinical (in vitro with PBMCs from 3 donors) and should not be extrapolated to human dosing without clinical confirmation.

With monoclonal antibodies in oncology: Phase I/II trials have explored combining beta-glucan with rituximab and pembrolizumab. The glucan primes neutrophils and macrophages via CR3 to recognize antibody-opsonized tumor cells. This is an emerging area with some early clinical signals but no phase III data as of mid-2026.

With vitamin C: Population studies and a few combination product trials in children suggest additive benefit for respiratory immunity, though isolating beta-glucan's contribution in multi-ingredient formulas is not feasible from available data (largely anecdotal at the isolated combination level).

Combinations with immunosuppressants should be avoided; see safety section.

Beta-Glucan Peptide is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Generally safe, rare allergic reactions

Beta-glucan preparations, including beta-glucan peptide complexes, have a generally favorable safety profile across clinical trials. No serious adverse events attributable to beta-glucan were recorded in the major systematic reviews of RCTs, and LD50 data in animal models (above 2,500 mg/kg for lentinan) indicate a wide margin.

Gastrointestinal effects: The most commonly reported adverse events across clinical trials are mild and transient GI complaints, including abdominal bloating, nausea, diarrhea, and loose stools. In the ABB C1 vaccine trial (n=72), 6 supplement and 4 placebo recipients reported minor GI events, with no causal distinction between groups. These effects appear dose-related and typically resolve without intervention.

Immunostimulatory risk in autoimmune conditions: Because beta-glucan upregulates macrophage, NK cell, and T cell activity, there is a theoretical risk of exacerbating autoimmune diseases (rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis). No published RCT data specifically quantify this risk, and the relevant evidence remains observational or theoretical. Individuals with active autoimmune conditions should consult a physician before use.

Organ transplant recipients: Beta-glucan's immune-activating properties create a theoretical risk of increased graft rejection in patients receiving calcineurin inhibitors or other immunosuppressants. No published clinical reports of rejection attributable to beta-glucan supplementation have been identified, but the pharmacodynamic conflict is well-reasoned and warrants medical supervision.

Immunostimulation during active infection: Because some beta-glucan responses include strong pro-inflammatory cytokine release (TNF-alpha, IL-6), use during severe systemic infection or sepsis requires caution; the same mechanism that enhances pathogen clearance may amplify inflammatory pathways.

One large multicentre trial (n=1,249, noted in PMC7770584) was terminated due to a higher adverse reaction frequency in the treatment arm; the preparations involved and specific adverse events were not detailed in available sources consulted.

Oral bioavailability: The PLOS ONE pilot (PMC4182605) found serum levels barely detectable after 1,000 mg/day oral dosing for 7 days, suggesting inconsistent systemic absorption with certain preparations; this may limit efficacy and reduce systemic side effect risk from oral routes simultaneously.